The prophylactic potential of fludarabine monophosphate in graft-versus-host disease after bone marrow transplantation in murine models.
Fludarabine phosphate, a purine analogue currently used in the therapy of hematological malignancies, is known to cause immunosuppression and long-lasting T cell lymphopenia. In this study, the effect of fludarabine on murine graft-versus-host disease occurring after marrow transplantation across major and minor histocompatibility barriers was evaluated. Survival of (BALB/c x C57BL/6)F1 mice irradiated and transplanted across the major histocompatibility barrier with C57BL/6 spleen cells, and subsequently treated with fludarabine was significantly longer than that of the control animals (P < 0.0001). On the other hand, fludarabine had no effect on the graft-versus-host disease and survival of CBA mice transplanted by B10.BR and of BALB/c mice transplanted by B10.D2 spleen cells across the minor histocompatability barrier. The results indicate that in certain murine models, particularly a major mismatch, fludarabine has the potential to induce bilateral tolerance and stable chimerism after marrow transplantation. Bone Marrow Transplantation (2000) 25, 263-266.
Or
R
R
Department of Bone Marrow Transplantation and Cancer Immunobiology Research Laboratory, Hadassah University Hospital and Hebrew University-Hadassah Medical School, Jerusalem, Israel.
Weiss
L
L
Amir
G
G
Tejman
S
S
Polliack
A
A
D000818:Animals; D016026:Bone Marrow Transplantation / Q000009:adverse effects* / Q000276:immunology; D004195:Disease Models, Animal; D006085:Graft Survival / Q000187:drug effects; D006086:Graft vs Host Disease / Q000517:prevention & control*; D006648:Histocompatibility / Q000276:immunology; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D008285:Major Histocompatibility Complex / Q000502:physiology; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D008912:Minor Histocompatibility Loci / Q000502:physiology; D015996:Survival Rate; D018183:Transplantation Chimera / Q000187:drug effects; D001084:Vidarabine Phosphate / Q000008:administration & dosage / Q000031:analogs & derivatives*; D015431:Weight Loss
D007166:Immunosuppressive Agents; D001084:Vidarabine Phosphate; C042382:fludarabine phosphate